🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06498349
Recruiting Not applicable

Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

NCT06498349 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2024-09-05
Last updated
2026-01-05

Condition(s) studied

Parkinson DiseaseImpulse Control Disorders

Investigational drug(s) / intervention(s)

bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatmentbest medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations

bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment: according to widely accepted expert consensus paper

best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.

Study summary

The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age at the time of enrollment: ≤ 70 years 2. Diagnosis of PD according to MDS clinical diagnostic criteria 3. Onset of first PD motor symptoms ≥ 4 years 4. Moderate or severe impulse control disorder or related behavioral disorders according to Ardouin, with at least 1 score greater than or equal to 3 (or at least 2 scores greater than or equal to 2) on the Ardouin behaviour scale with the following items considered to reflect ICBDs or related behaviors: pathological gambling, hypersexuality, shopping, eating, hobbyism, punding and compulsive medication use 5. MDS-UPDRS III improvement of ≥ 30% in the standardized levodopa test or classical Parkinsonian tremor at rest 6. Adaptation of medical therapy has been attempted 7. MoCA ≥ 24 in the meds on condition 8. BDI-II score \< 20 in the meds on condition, or Patients with moderately severe depression with a BDI-II between 20 and 28 points, strict consideration must be made with the involvement of a psychiatrist. Patients must be willing and able to comply this. 9. Patients able to understand the study requirements and the treatment procedures 10. Written informed consent before any study-specific tests or procedures are performed Exclusion Criteria: 11. Surgical contraindications to undergo DBS operation 12. Ongoing severe depression (BDI-II \> 28) 13. suicidal ideation (item 9 of BDI-II \> 1) 14. Dementia (MoCA \< 24) in the meds on condition 15. Any prior movement disorder treatments that involved intracranial surgery/ablation or intracranial device implantation 16. Any other active implanted device that is likely to interfere with the implantation or functioning of the DBS system 17. Simultaneous participation in another clinical trial targeting or potentially interfering with ICD 18. Any history of recurrent seizures or haemorrhagic stroke 19. Fertile women not using adequate contraceptive methods 20. Any terminal illness with significantly reduced life expectancy which exclude DBS implantation according to standard clinical care 21. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception 22. Any impairment that would limit subject's ability to participate in the study and perform study procedures 23. Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
University Hospital Cologne Cologne Germany Recruiting
University Hospital Carl Gustav Carus Dresden Germany Recruiting
University Hospital Duesseldorf Düsseldorf Germany Recruiting
University Medical Center Hamburg-Eppendorf Hamburg Germany Recruiting
University Hospital Schleswig-Holstein (UKSH), Campus Kiel Kiel Germany Recruiting
University Hospital of Giessen and Marburg (UKGM), Campus Marburg Marburg Germany Recruiting
Charité Campus Mitte Mitte Germany Recruiting
University Hospital Tuebingen Tübingen Germany Recruiting
University Hospital Wuerzburg Würzburg Germany Recruiting
Amsterdam University Medical Center Amsterdam Netherlands Recruiting
University Hospital of Bern (Inselspital) Bern Switzerland Recruiting
University Hospital Zuerich (USZ) Zurich Switzerland Recruiting

More University of Kiel trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06498349 on ClinicalTrials.gov ↗ ← All trials in Germany